NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...
While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...
The KP.3 variant of SARS-CoV-2 is dominating in Canada right now, accounting for the majority of the COVID-19 cases in the ...
NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...
An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease ...
Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.